Macrophages, which flood the intestines’ lining, release cytokines that trigger significant inflammation, leading to the discomfort and symptoms associated with IBD. The researchers found that the enhancer is the “master regulator” of inflammation in these cells, sitting “at the top of the pyramid,” as Dr. Lee described.

Dr. Lee further explained, “This is undoubtedly one of the central pathways that goes wrong for people to get inflammatory bowel disease. It is the process by which one of the most important cells that causes inflammatory bowel disease goes wrong.”

Labeling it a “holy grail” discovery, Dr. Lee mentioned that existing drugs approved for other diseases, such as cancer, could reduce this inflammation. However, these drugs need adjustments to specifically target macrophages in IBD patients. He hopes that clinical trials could begin within five years, offering new hope for those affected by the condition.

Currently, about half a million people in the UK suffer from some form of IBD, with Crohn’s disease and ulcerative colitis being the most common. Symptoms typically include diarrhea, stomach pain or cramps, blood in the stool, bleeding from the rectum, fatigue, and unexplained weight loss.

While there’s an overlap between IBD and similar conditions like irritable bowel syndrome (IBS), IBD can be distinguished by the inflammation it causes in the bowels. Until now, the NHS has described the cause of IBD as unclear, attributing it to the immune system attacking the bowel and causing inflammation. However, this latest research makes the cause much clearer, suggesting it’s time for updates in medical literature and treatment approaches.